Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Charles River Laboratories International : Q3 2020 Earnings Presentation

10/29/2020 | 06:20am EDT

3Q 2020 Results

October 29, 2020

Charles River Laboratories


© 2020 Charles River Laboratories International, Inc.

Safe Harbor Statement

Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements about the impact of the COVID-19 pandemic for our business, financial condition and results of operations, including the long-term growth prospects and as compared to other companies, and the prospects for recovery therefrom; the effectiveness of our capital deployment strategy, including the pace of our M&A activity and re-evaluation of capital projects, in light of the COVID-19 pandemic and our ability to reduce capex, preserve jobs, support client research programs and sustain our financial position; our compliance with the maintenance covenants under our credit agreement; our projected 2020 and other future financial performance whether reported, organic, and/or factoring acquisitions, with respect to Charles River as a whole and/or any of our reporting or operating segments or business units; our annual guidance and two-year targets; the assumptions surrounding the COVID-19 pandemic that form the basis for our revised annual guidance; the expected performance of our venture capital and other strategic investments; the future demand for drug discovery and development products and services, and our intentions to expand those businesses, including our investments in our portfolio; the impact of foreign exchange; our expectations regarding stock repurchases and debt repayment; the development and performance of our services and products; market and industry conditions, including industry consolidation, outsourcing of services and identification of spending trends by our clients and funding available to them; our business strategy, including with respect to capital deployment and leverage; our success in identifying, consummating, and integrating, and the impact of, our acquisitions, on the Company, our service offerings, client perception, strategic relationships, revenue, revenue growth rates, earnings, and synergies; our expectations regarding HemaCare's and Cellero's financial performance; our strategic agreements with our clients and opportunities for future similar arrangements; our ability to obtain new clients in targeted market segments and/or to predict which client segments will be future growth drivers; the impact of our investments in specified business lines, products, sites and geographies; and Charles River's future performance as otherwise delineated in our forward-looking guidance.

Forward-looking statements are based on Charles River's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the COVID-19 pandemic, its duration, its impact on our business, results of operations, financial condition, liquidity, business practices, operations, suppliers, third party service providers, customers, employees, industry, ability to meet future performance obligations, ability to efficiently implement advisable safety precautions, and internal controls over financial reporting; the COVID-19 pandemic's impact on demand, the global economy and financial markets; the ability to successfully integrate businesses we acquire; the ability to execute our cost-savings actions and the steps to optimize returns to shareholders on an effective and timely basis; the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our clients; the ability to convert backlog to revenue; special interest groups; contaminations; industry trends; new displacement technologies; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in regulations by the FDA, USDA, or other global regulatory agencies; changes in law; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 11, 2020 and the Quarterly Report on Form 10-Q as filed on August 5, 2020, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this presentation except as required by law.

Regulation G

This presentation includes discussion of non-GAAP financial measures. W e believe that the inclusion of these non-GAAP financial measures provides useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of often one-time charges, consistent with the manner in which management measures and forecasts the Company's performance. The non-GAAP financial measures included in this presentation are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. The company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. In accordance with Regulation G, you can find the comparable GAAP measures and reconciliations to those GAAP measures on our website at ir.criver.com.


Estimates of COVID-19 Impact

The Company has provided its estimates for the impact from the COVID-19 pandemic, including on the Company's revenue. These estimates were determined using methodologies and assumptions that vary depending on the specific reporting segment and situation. For the Research Models and Services segment, estimates were primarily based on comparisons to daily historical research model sales volumes prior to the COVID-19 pandemic and the subsequent reduction in research model order activity associated with our clients' COVID-19pandemic-related site closures and/or their reduced on-site activity, as well as our discussions with clients, particularly of our research model services and HemaCare businesses, with regard to revenue expectations and operational impacts from the COVID-19 pandemic. For the Discovery and Safety Assessment segment, estimates were based on multiple factors including, but not limited to, discussions with clients with regard to the cause of delays to discovery projects and safety assessment studies, location-specific actions to ensure employee safety in our facilities, the impact of remote versus in-person activities and services, and supply chain delays and other resource constraints. For the Manufacturing Support segment, estimates were based on multiple factors including, but not limited to, analysis of the sales impact due to the COVID-19 pandemic, assessments of idle instruments and the related revenue stream due to the inability to access clients' sites, as well as discussions with clients with regard to their revenue expectations and operations. Further, we assumed for the purposes of formulating these estimates that (1) restrictions on economic activity, including stay-in-place orders and other similar government actions, will largely not be re-imposed for the remainder of the fiscal year; (2) the global economy, as it relates to demand for Charles River's products and services, will gradually improve through the remainder of 2020; and (3) most of the Company's essential personnel will be able to work on-site and that it will have the adequate supplies and resources to support its businesses. In addition, the estimated revenue loss related to COVID-19 is expected to be partially offset by incremental work on clients' COVID-19 programs. Because these estimates and assumptions involve risks and uncertainties, actual events and results may differ materially from these estimates and assumptions, and Charles River assumes no obligation and expressly disclaims any duty to update them.


Response to Global COVID-19 Pandemic

  • Global pandemic is continuing to adversely affect our world
  • Biopharmaceutical industry is distinguishing itself, leading the way in scientific innovation that will be vital to finding a cure for COVID-19
  • At Charles River, we have never been so essential to our diverse and growing client base, as we remain fully operational and continue to enable biopharma clients to move their programs forward across a wide range of therapeutic areas, including COVID-19
  • Our resilience through the pandemic has enhanced our position as the partner of choice for our clients' early-stage research needs, as we continue to differentiate ourselves through our broad portfolio, scientific expertise, and superb client service


This is an excerpt of the original content. To continue reading it, access the original document here.


Charles River Laboratories International Inc. published this content on 29 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 October 2020 11:19:05 UTC

ę Publicnow 2020
06/23COMBIGENEá : GMP plasmids released - Ready to start GMP production of CG01
06/07CHARLES RIVER LABORATORIES INTERNATI : Signs Long-Term Solar Contract With Duke ..
06/07CHARLES RIVER LABORATORIES INTERNATI : Announces Long-Term Solar Contract for No..
06/02INSIDER TRENDS : Insider at Charles River Labs International Tax Sale Continues ..
05/28CHARLES RIVER LABORATORIES INTERNATI : UBS Adjusts Price Target on Charles River..
05/28CHARLES RIVER LABORATORIES INTERNATI : JPMorgan Adjusts Price Target on Charles ..
05/28CHARLES RIVER LABORATORIES INTERNATI : Credit Suisse Raises Charles River Labora..
05/28CHARLES RIVER LABORATORIES INTERNATI : to Participate in June Investor Conferenc..
05/28CHARLES RIVER LABORATORIES INTERNATI : Citigroup Adjusts Price Target on Charles..
05/27CHARLES RIVER LABORATORIES INTERNATI : 2021 Meeting with Management Presentation
More news
Financials (USD)
Sales 2021 3 513 M - -
Net income 2021 328 M - -
Net Debt 2021 1 604 M - -
P/E ratio 2021 57,2x
Yield 2021 -
Capitalization 18 440 M 18 440 M -
EV / Sales 2021 5,70x
EV / Sales 2022 5,07x
Nbr of Employees 18 400
Free-Float 98,2%
Duration : Period :
Charles River Laboratories International, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 16
Last Close Price 366,95 $
Average target price 361,64 $
Spread / Average Target -1,45%
EPS Revisions
Managers and Directors
James C. Foster Chairman, President & Chief Executive Officer
David Ross Smith Chief Financial Officer & Executive Vice President
Arthur C. Hubbs Chief Information Officer & Senior Vice President
Matthew L. Daniel Secretary & Chief Compliance Officer
Barbara j. Patterson Senior VP-Regulatory Affairs & Compliance
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.102.97%88 882
LONZA GROUP AG14.06%52 367
CELLTRION, INC.-21.59%32 903
SEAGEN INC.-10.43%28 797